Epidemiological and Clinical Insights into Acinetobacter baumannii: A Six-Year Study on Age, Antibiotics, and Specimens
Yousef Almoghrabi,Hussam Daghistani,Hanouf Niyazi,Hatoon Niyazi,Hind AbdulMajed,Noha Juma,Noura Daffa,Noof Helmi,Mohammed Al-Rabia,Jawahir Mokhtar,Bandar Saleh,Dalya Attallah,Maram Matar,Hani Shukri,Shahd Moqaddam,Sara Alamoudi,Khalil Alkuwaity,Turki Abujamel,Ahmad Sait,Mohammed Mufrrih,Ibrahim Al-Zahrani,Stephen O'hagan,Mazen Ismail,Ohood Alharbi,Hattan Momin,Ibrahim Abu,Abdelbagi Alfadil,Karem Ibrahem
DOI: https://doi.org/10.2147/ijgm.s489514
IF: 2.145
2024-12-04
International Journal of General Medicine
Abstract:Yousef Almoghrabi, 1, 2, &ast Hussam Daghistani, 1, 2, &ast Hanouf A Niyazi, 3, &ast Hatoon A Niyazi, 3, &ast Hind AbdulMajed, 3, &ast Noha A Juma, 3, &ast Noura Daffa, 3, &ast Noof R Helmi, 3, &ast Mohammed W Al-Rabia, 3, 4, &ast Jawahir A Mokhtar, 3, 5, 6, &ast Bandar Hasan Saleh, 3, &ast Dalya M Attallah, 5 Maram Matar, 5 Hani Ahmed Shukri, 5 Shahd A Moqaddam, 5 Sara Alamoudi, 5 Khalil K Alkuwaity, 6, 7, &ast Turki Abujamel, 6, 7, &ast Ahmad M Sait, 2, 7 Mohammed Mufrrih, 7, 8 Ibrahim A Al-Zahrani, 7, 8, &ast Stephen O'hagan, 9 Mazen A Ismail, 10, &ast Ohood S Alharbi, 11, &ast Hattan Jamal Momin, 12, &ast Ibrahim Mohammed Abu, 13, &ast Abdelbagi Alfadil, 3, 4, &ast Karem Ibrahem 3 1 Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 2 Regenerative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 3 Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 4 Centre of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia; 5 Department of Clinical Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah, 21589, Saudi Arabia; 6 Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 7 Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 8 Special Infectious Agents Unit BSL-3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 9 Department of Chemistry, Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK; 10 Department of Medical Education, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 11 Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; 12 Medical Service Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 13 Department of Community Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia &astThese authors contributed equally to this work Correspondence: Karem Ibrahem, Email Background: This six-year retrospective study provides an in-depth analysis of the epidemiological and clinical patterns associated with Acinetobacter baumannii ( A. baumannii ) infections, focusing on age distribution, antibiotic resistance profiles, and specimen types. Aim: The research examines the incidence and characteristics of both non-Multi-Drug Resistant (non-MDR) and Multi-Drug Resistant (MDR) A. baumannii strains by reviewing patient records from January 2016 to December 2022. Methods: Through a statistical analysis, the study highlights the incidence rates across diverse age groups and explores the impact of antibiotic treatment regimens on infection outcomes. Additionally, it identifies the primary clinical specimen types for each strain, noting an association between non-MDR A. baumannii and midstream urine samples, while MDR A. baumannii strains were more frequently found in respiratory, wound, peripheral, and central line swaps/specimens. Results: The results indicate that in 2016, non-MDR A. baumannii infections were notably more frequent compared to MDR A. baumannii cases. However, a significant shift occurred in 2021 and 2022, with a marked decrease in non-MDR A. baumannii cases and an increase in MDR A. baumannii infections. Antibiotic susceptibility testing revealed that non-MDR strains were commonly tested against cefazolin, ceftazidime, ciprofloxacin, gentamicin, nitrofurantoin, oxacillin, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole. In contrast, MDR strains were frequently tested against amikacin, cefepime, colistin, meropenem, imipenem, and tigecycline. Conclusion -Abstract Truncated-
medicine, general & internal